- Home
- NEOV vs GNLX Comparison
NEOV vs GNLX Comparison
Compare NEOV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NEOV | GNLX |
|---|---|---|
| Founded | 2018 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.2M | 110.4M |
| IPO Year | 2022 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NEOV | GNLX |
|---|---|---|
| Price | $2.48 | $2.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $9.75 | ★ $18.83 |
| AVG Volume (30 Days) | ★ 1.3M | 201.1K |
| Earning Date | 11-09-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,332,953.00 | $8,000.00 |
| Revenue This Year | $623.96 | N/A |
| Revenue Next Year | $344.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 58.22 | N/A |
| 52 Week Low | $1.36 | $2.29 |
| 52 Week High | $7.13 | $8.54 |
Technical Indicators
Market Signals| Indicator | NEOV | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 46.39 |
| Support Level | $1.94 | $2.32 |
| Resistance Level | $3.21 | $2.68 |
| Average True Range (ATR) | 0.20 | 0.11 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 37.06 | 36.00 |
Price Performance
Historical ComparisonAbout NEOV NeoVolta Inc.
NeoVolta Inc is engaged in designing, manufacturing and sale of high end Energy Storage System which can store and use solar energy via batteries and an inverter at a residential site. Its market place includes solar industry, installers, new construction homebuilders, home remodelers and homeowners.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.